破坏肿瘤细胞N-聚糖表达可增强嵌合抗原受体T细胞对实体恶性肿瘤的疗效
该研究显示多种癌表达细胞外N-聚糖,其丰度与CAR T细胞杀伤负相关;在胰腺腺癌中敲除MGAT5证实N-聚糖通过干扰免疫突触形成等保护肿瘤。用2-脱氧-d-葡萄糖(2DG)抑制N-聚糖合成可增强CAR T细胞活性并减少耗竭,在多种实体瘤小鼠模型中有效。
要点
- 肿瘤细胞外N-聚糖丰度与CAR T细胞杀伤呈负相关。
- 敲除MGAT5去除N-聚糖可改善免疫突触形成和CAR T细胞功能。
- 2DG抑制N-聚糖合成增强CAR T细胞对多种实体瘤的活性。
核心结论
- 肿瘤N-糖基化调控CAR T细胞应答的质量和强度,为合理设计改良实体恶性肿瘤疗法铺路。
研究设计与样本
- 研究在胰腺腺癌(PAC)中敲除甘露糖苷乙酰葡糖胺转移酶5(MGAT5),并在多种PAC异种移植小鼠模型中用葡萄糖/甘露糖类似物2-脱氧-d-葡萄糖(2DG)抑制N-聚糖合成。
主要发现
- 多种癌表达细胞外N-聚糖,其丰度与CAR T细胞杀伤负相关。
- 在PAC中敲除MGAT5显示N-聚糖通过干扰适当免疫突触形成并降低转录激活、细胞因子产生和细胞毒性保护肿瘤免受CAR T细胞杀伤。
- 2DG处理破坏肿瘤细胞N-聚糖覆盖,在不同PAC异种移植小鼠模型中增强CAR T细胞活性。
- 2DG处理干扰PD-1–PD-L1轴,体内减少肿瘤浸润CAR T细胞的耗竭谱。
- 2DG联合CAR T细胞疗法对除PAC外的多种癌(包括肺癌、卵巢癌和膀胱癌)以及不同临床相关CAR特异性(如CD44v6和CEA)有效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy with chimeric antigen receptor (CAR)–engineered T cells showed exceptional successes in patients with refractory B cell malignancies. However, first-in-human studies in solid tumors revealed unique hurdles contributing to poor demonstration of efficacy. Understanding the determinants of tumor recognition by CAR T cells should translate into the design of strategies that can overcome resistance. Here, we show that multiple carcinomas express extracellular N-glycans, whose abundance negatively correlates with CAR T cell killing. By knocking out mannoside acetyl-glucosaminyltransferase 5 (MGAT5) in pancreatic adenocarcinoma (PAC), we showed that N-glycans protect tumors from CAR T cell killing by interfering with proper immunological synapse formation and reducing transcriptional activation, cytokine production, and cytotoxicity. To overcome this barrier, we exploited the high metabolic demand of tumors to safely inhibit N-glycans synthesis with the glucose/mannose analog 2-deoxy-d-glucose (2DG). Treatment with 2DG disrupts the N-glycan cover on tumor cells and results in enhanced CAR T cell activity in different xenograft mouse models of PAC. Moreover, 2DG treatment interferes with the PD-1–PD-L1 axis and results in a reduced exhaustion profile of tumor-infiltrating CAR T cells in vivo. The combined 2DG and CAR T cell therapy was successful against multiple carcinomas besides PAC, including those arising from the lung, ovary, and bladder, and with different clinically relevant CAR specificities, such as CD44v6 and CEA. Overall, our results indicate that tumor N-glycosylation regulates the quality and magnitude of CAR T cell responses, paving the way for the rational design of improved therapies against solid malignancies.
引用
- Greco B, Malacarne V, De Girardi F, et al. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. Sci Transl Med. 2022. PMID: 35044789. doi:10.1126/scitranslmed.abg3072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。